Cargando…

Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome

Despite known histological, biological, and clinical differences between lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), relatively little is known about the spatial differences in their corresponding immune contextures. Our study of over 1000 LUAD and LUSC tumors revealed that comput...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Ruiwen, Prasanna, Prateek, Corredor, Germán, Barrera, Cristian, Zens, Philipp, Lu, Cheng, Velu, Priya, Leo, Patrick, Beig, Niha, Li, Haojia, Toro, Paula, Berezowska, Sabina, Baxi, Vipul, Balli, David, Belete, Merzu, Rimm, David L., Velcheti, Vamsidhar, Schalper, Kurt, Madabhushi, Anant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166700/ https://www.ncbi.nlm.nih.gov/pubmed/35661148 http://dx.doi.org/10.1038/s41698-022-00277-5

Ejemplares similares

Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer
por: Barrera, Cristian, et al.
Publicado: (2023)

A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study
por: Lu, Cheng, et al.
Publicado: (2020)

Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas
por: Alilou, Mehdi, et al.
Publicado: (2018)

Author Correction: Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas
por: Alilou, Mehdi, et al.
Publicado: (2019)

Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors
por: Wang, Xiangxue, et al.
Publicado: (2022)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
por: Carvajal-Hausdorf, Daniel, et al.
Publicado: (2019)

Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images
por: Wang, Xiangxue, et al.
Publicado: (2017)

A tumor vasculature–based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors
por: Alilou, Mehdi, et al.
Publicado: (2022)

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Mass Effect Deformation Heterogeneity (MEDH) on Gadolinium-contrast T1-weighted MRI is associated with decreased survival in patients with right cerebral hemisphere Glioblastoma: A feasibility study
por: Prasanna, Prateek, et al.
Publicado: (2019)

A Novel Nodule Edge Sharpness Radiomic Biomarker Improves Performance of Lung-RADS for Distinguishing Adenocarcinomas from Granulomas on Non-Contrast CT Scans
por: Alilou, Mehdi, et al.
Publicado: (2021)

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
por: Lopez de Rodas, Miguel, et al.
Publicado: (2022)

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
por: Velcheti, Vamsidhar, et al.
Publicado: (2013)

Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma
por: Beig, Niha, et al.
Publicado: (2018)

Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)

Radiomic Deformation and Textural Heterogeneity (R-DepTH) Descriptor to Characterize Tumor Field Effect: Application to Survival Prediction in Glioblastoma
por: Ismail, Marwa, et al.
Publicado: (2022)

A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer
por: Wang, Xiangxue, et al.
Publicado: (2021)

Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe): A new radiomics descriptor
por: Prasanna, Prateek, et al.
Publicado: (2016)

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
por: Vaidya, Pranjal, et al.
Publicado: (2020)

Single cell qPCR reveals that additional HAND2 and microRNA-1 facilitate the early reprogramming progress of seven-factor-induced human myocytes
por: Bektik, Emre, et al.
Publicado: (2017)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer
por: Braman, Nathaniel, et al.
Publicado: (2019)

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab
por: Khunger, Monica, et al.
Publicado: (2017)

Radiomics and radiogenomics in gliomas: a contemporary update
por: Singh, Gagandeep, et al.
Publicado: (2021)

Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
por: Velcheti, Vamsidhar, et al.
Publicado: (2015)

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
por: Gettinger, S. N., et al.
Publicado: (2018)

Introduction to radiomics and radiogenomics in neuro-oncology: implications and challenges
por: Beig, Niha, et al.
Publicado: (2021)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018)

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
por: Khunger, Arjun, et al.
Publicado: (2018)

Fysikkpris til Fanamann
Publicado: (1981)

Petabytes til folket
Publicado: (2005)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

The state of the art for artificial intelligence in lung digital pathology
por: Viswanathan, Vidya Sankar, et al.
Publicado: (2022)

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
por: Teng, Feifei, et al.
Publicado: (2016)

High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy
por: Jia, Wenxiao, et al.
Publicado: (2023)

Combined Radiomic and Visual Assessment for Improved Detection of Lung Adenocarcinoma Invasiveness on Computed Tomography Scans: A Multi-Institutional Study
por: Vaidya, Pranjal, et al.
Publicado: (2022)

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
por: Braman, Nathaniel M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_27do3tv2vmvoi6gjjcv6it17tg